

Global Peptide-Drug Conjugates(PDCs) CDMO Service Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G9F692F6E2CFEN.html>

Date: June 2026

Pages: 115

Price: US\$ 4,480.00 (Single User License)

ID: G9F692F6E2CFEN

Abstracts

The global Peptide-Drug Conjugates(PDCs) CDMO Service market size is expected to reach \$ 1847 million by 2032, rising at a market growth of 17.2% CAGR during the forecast period (2026-2032).

Peptide-Drug Conjugates (PDCs) CDMO Service refers to contract development and manufacturing services for peptide-drug conjugates, typically covering peptide synthesis, linker and payload integration, conjugation process development, analytical method development and validation, quality studies, technology transfer, GMP manufacturing, scale-up, and commercial supply. The core of this service lies in achieving stable conjugation between peptide molecules, linkers, and small-molecule payloads while meeting the requirements for quality consistency, scalability, and regulatory compliance across drug development and commercialization stages. The upstream supply chain mainly includes protected amino acids, specialty amino acids, resin supports, linkers, cytotoxic payloads or other active small molecules, conjugation reagents, organic solvents, purification media, analytical consumables, and GMP packaging materials, while the main downstream customers are innovative pharmaceutical companies, biotechnology firms, and drug developers engaged in targeted delivery, peptide conjugates, and other novel conjugated modalities. The global gross margin of PDC CDMO services in 2025 is estimated at 30%-45%.

The PDC CDMO service market is currently moving from a stage focused on technical validation toward one centered on industrialization capability and integrated execution. As peptides gain broader value as targeting carriers and functional recognition elements, customer demand is no longer limited to peptide synthesis alone. Greater importance is now placed on linker design, payload integration, conjugation robustness, analytical characterization, and scalability in manufacturing. For clients, service

providers that can combine peptide synthesis, conjugation development, quality studies, and GMP manufacturing within one platform are becoming increasingly attractive, and competition is gradually shifting from isolated technical strengths to comprehensive delivery capability.

From a technology perspective, the market is expected to place greater emphasis on selective conjugation, advanced molecular characterization, impurity profile control, and consistency during scale-up. PDCs involve the integration of multiple components and present complex structural and quality attributes, which means development programs require strong capabilities in analytical methods, purification strategy, and process control. As more projects advance into later clinical stages, service providers will need to strengthen their expertise in peptide modification, linker chemistry, payload handling, and high-sensitivity analytical testing. At the same time, expectations for process robustness, batch consistency, and regulatory support will continue to increase.

The main drivers of market growth come from rising demand for novel targeted therapeutics, the gradual maturation of peptide conjugation technologies, and the growing willingness of innovative drug developers to outsource complex modalities. More pharmaceutical and biotechnology companies are relying on specialized external partners to reduce internal infrastructure costs, accelerate development timelines, and manage the complexity of integrating peptide, linker, and payload technologies. In addition, the expanding application potential of peptide-based conjugates in oncology, metabolic diseases, and other precision delivery fields continues to support demand for specialized CDMO services. As clinical programs accumulate and the supporting supply chain becomes more established, the market is likely to continue moving toward greater specialization and scale.

At the same time, the market faces several important constraints. PDC development depends on multiple critical steps, including peptide synthesis, linker selection, payload integration, and conjugation process control, and weakness in any one area can affect overall quality and development progress. The transition from laboratory development to GMP manufacturing also places much higher demands on production environments, analytical systems, documentation, and quality management, requiring sustained investment in equipment, talent, and compliance infrastructure. In addition, because the sector remains at a relatively early stage, project flow, commercialization maturity, and customer onboarding can still fluctuate, which means companies must carefully balance capacity expansion with actual order conversion. Over the longer term, the most competitive providers are likely to be those that can combine technical depth, development efficiency, quality systems, and industrial execution within an integrated

service platform.

This report studies the global Peptide-Drug Conjugates(PDCs) CDMO Service demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Peptide-Drug Conjugates(PDCs) CDMO Service, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide-Drug Conjugates(PDCs) CDMO Service that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Peptide-Drug Conjugates(PDCs) CDMO Service total market, 2021-2032, (USD Million)

Global Peptide-Drug Conjugates(PDCs) CDMO Service total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Peptide-Drug Conjugates(PDCs) CDMO Service total market, key domestic companies, and share, (USD Million)

Global Peptide-Drug Conjugates(PDCs) CDMO Service revenue by player, revenue and market share 2021-2026, (USD Million)

Global Peptide-Drug Conjugates(PDCs) CDMO Service total market by Type, CAGR, 2021-2032, (USD Million)

Global Peptide-Drug Conjugates(PDCs) CDMO Service total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Peptide-Drug Conjugates(PDCs) CDMO Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include WuXi TIDES, Porton, PeptiStar, Jiuzhou Pharmaceutical, CPC Scientific, Creative Peptides, Viva Biotech, KriSan Biotech, ChemExpress, CordenPharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Peptide-Drug Conjugates(PDCs) CDMO Service market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market, Segmentation by Type:

GMP Services

Non-GMP Services

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market, Segmentation by Capacity Tier:

Small-Scale Production

Pilot-Scale Production

Commercial-Scale Production

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market, Segmentation by Therapeutic Area:

Oncology

Metabolic Diseases

Cardiovascular Diseases

Infectious Diseases

Neurological Disorder

Other

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market, Segmentation by Application:

Pharmaceutical Companies

Biotechnology Companies

Academic and Research Institutions

Others

Companies Profiled:

WuXi TIDES

Porton

PeptiStar

Jiuzhou Pharmaceutical

CPC Scientific

Creative Peptides

Viva Biotech

KriSan Biotech

ChemExpress

CordenPharma

Almac Group

AmbioPharm

Key Questions Answered

1. How big is the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
2. What is the demand of the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
3. What is the year over year growth of the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
4. What is the total value of the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
5. Who are the Major Players in the global Peptide-Drug Conjugates(PDCs) CDMO Service market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Peptide-Drug Conjugates(PDCs) CDMO Service Introduction
- 1.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Peptide-Drug Conjugates(PDCs) CDMO Service Total Market by Region (by Headquarter Location)
 - 1.3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032)
 - 1.3.3 China Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032)
 - 1.3.4 Europe Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032)
 - 1.3.5 Japan Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032)
 - 1.3.6 South Korea Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032)
 - 1.3.8 India Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032)
- 2.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region
 - 2.2.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region (2021-2026)
 - 2.2.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value

Forecast by Region (2027-2032)

2.3 United States Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032)

2.4 China Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032)

2.5 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032)

2.6 Japan Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032)

2.7 South Korea Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032)

2.8 ASEAN Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032)

2.9 India Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032)

3 WORLD PEPTIDE-DRUG CONJUGATES(PDCS) CDMO SERVICE COMPANIES COMPETITIVE ANALYSIS

3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Player (2021-2026)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Peptide-Drug Conjugates(PDCs) CDMO Service in 2025

3.2.3 Global Concentration Ratios (CR8) for Peptide-Drug Conjugates(PDCs) CDMO Service in 2025

3.3 Peptide-Drug Conjugates(PDCs) CDMO Service Company Evaluation Quadrant

3.4 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Overall Company Footprint Analysis

3.4.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Region Footprint

3.4.2 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Type Footprint

3.4.3 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)

4.1.2 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share Comparison (2021 & 2025 & 2032)

4.2 United States Based Companies VS China Based Companies: Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Comparison

4.2.1 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Comparison (2021 & 2025 & 2032)

4.2.2 United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share Comparison (2021 & 2025 & 2032)

4.3 United States Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies and Market Share, 2021-2026

4.3.1 United States Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, (2021-2026)

4.4 China Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Market Share, 2021-2026

4.4.1 China Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, (2021-2026)

4.5 Rest of World Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies and Market Share, 2021-2026

4.5.1 Rest of World Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 GMP Services

5.2.2 Non-GMP Services

5.3 Market Segment by Type

5.3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2021-2026)

5.3.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2027-2032)

5.3.3 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY CAPACITY TIER

6.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Overview by Capacity Tier: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Capacity Tier

6.2.1 Small-Scale Production

6.2.2 Pilot-Scale Production

6.2.3 Commercial-Scale Production

6.3 Market Segment by Capacity Tier

6.3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Capacity Tier (2021-2026)

6.3.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Capacity Tier (2027-2032)

6.3.3 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Capacity Tier (2027-2032)

7 MARKET ANALYSIS BY THERAPEUTIC AREA

7.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Overview by Therapeutic Area: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Therapeutic Area

7.2.1 Oncology

7.2.2 Metabolic Diseases

7.2.3 Cardiovascular Diseases

7.2.4 Infectious Diseases

7.2.5 Neurological Disorder

7.2.6 Other

7.3 Market Segment by Therapeutic Area

7.3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Therapeutic Area (2021-2026)

7.3.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Therapeutic Area (2027-2032)

7.3.3 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Therapeutic Area (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Overview by Application: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Application

8.2.1 Pharmaceutical Companies

8.2.2 Biotechnology Companies

8.2.3 Academic and Research Institutions

8.2.4 Others

8.3 Market Segment by Application

8.3.1 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026)

8.3.2 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2027-2032)

8.3.3 World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 WuXi TIDES

9.1.1 WuXi TIDES Details

9.1.2 WuXi TIDES Major Business

9.1.3 WuXi TIDES Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

9.1.4 WuXi TIDES Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

9.1.5 WuXi TIDES Recent Developments/Updates

9.1.6 WuXi TIDES Competitive Strengths & Weaknesses

9.2 Porton

9.2.1 Porton Details

9.2.2 Porton Major Business

9.2.3 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

9.2.4 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

9.2.5 Porton Recent Developments/Updates

9.2.6 Porton Competitive Strengths & Weaknesses

9.3 PeptiStar

9.3.1 PeptiStar Details

9.3.2 PeptiStar Major Business

9.3.3 PeptiStar Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

9.3.4 PeptiStar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

9.3.5 PeptiStar Recent Developments/Updates

9.3.6 PeptiStar Competitive Strengths & Weaknesses

9.4 Jiuzhou Pharmaceutical

9.4.1 Jiuzhou Pharmaceutical Details

9.4.2 Jiuzhou Pharmaceutical Major Business

9.4.3 Jiuzhou Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

9.4.4 Jiuzhou Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

9.4.5 Jiuzhou Pharmaceutical Recent Developments/Updates

9.4.6 Jiuzhou Pharmaceutical Competitive Strengths & Weaknesses

9.5 CPC Scientific

9.5.1 CPC Scientific Details

9.5.2 CPC Scientific Major Business

9.5.3 CPC Scientific Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

9.5.4 CPC Scientific Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

9.5.5 CPC Scientific Recent Developments/Updates

9.5.6 CPC Scientific Competitive Strengths & Weaknesses

9.6 Creative Peptides

9.6.1 Creative Peptides Details

9.6.2 Creative Peptides Major Business

9.6.3 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

9.6.4 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

- 9.6.5 Creative Peptides Recent Developments/Updates
- 9.6.6 Creative Peptides Competitive Strengths & Weaknesses
- 9.7 Viva Biotech
 - 9.7.1 Viva Biotech Details
 - 9.7.2 Viva Biotech Major Business
 - 9.7.3 Viva Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 - 9.7.4 Viva Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
 - 9.7.5 Viva Biotech Recent Developments/Updates
 - 9.7.6 Viva Biotech Competitive Strengths & Weaknesses
- 9.8 KriSan Biotech
 - 9.8.1 KriSan Biotech Details
 - 9.8.2 KriSan Biotech Major Business
 - 9.8.3 KriSan Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 - 9.8.4 KriSan Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
 - 9.8.5 KriSan Biotech Recent Developments/Updates
 - 9.8.6 KriSan Biotech Competitive Strengths & Weaknesses
- 9.9 ChemExpress
 - 9.9.1 ChemExpress Details
 - 9.9.2 ChemExpress Major Business
 - 9.9.3 ChemExpress Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 - 9.9.4 ChemExpress Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
 - 9.9.5 ChemExpress Recent Developments/Updates
 - 9.9.6 ChemExpress Competitive Strengths & Weaknesses
- 9.10 CordenPharma
 - 9.10.1 CordenPharma Details
 - 9.10.2 CordenPharma Major Business
 - 9.10.3 CordenPharma Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
 - 9.10.4 CordenPharma Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
 - 9.10.5 CordenPharma Recent Developments/Updates
 - 9.10.6 CordenPharma Competitive Strengths & Weaknesses
- 9.11 Almac Group

- 9.11.1 Almac Group Details
- 9.11.2 Almac Group Major Business
- 9.11.3 Almac Group Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
- 9.11.4 Almac Group Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
- 9.11.5 Almac Group Recent Developments/Updates
- 9.11.6 Almac Group Competitive Strengths & Weaknesses
- 9.12 AmbioPharm
- 9.12.1 AmbioPharm Details
- 9.12.2 AmbioPharm Major Business
- 9.12.3 AmbioPharm Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services
- 9.12.4 AmbioPharm Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
- 9.12.5 AmbioPharm Recent Developments/Updates
- 9.12.6 AmbioPharm Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

- 10.1 Peptide-Drug Conjugates(PDCs) CDMO Service Industry Chain
- 10.2 Peptide-Drug Conjugates(PDCs) CDMO Service Upstream Analysis
- 10.3 Peptide-Drug Conjugates(PDCs) CDMO Service Midstream Analysis
- 10.4 Peptide-Drug Conjugates(PDCs) CDMO Service Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

- 12.1 Methodology
- 12.2 Research Process and Data Source
- 12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key Peptide-Drug Conjugates(PDCs) CDMO Service Players in 2025

Table 12. World Peptide-Drug Conjugates(PDCs) CDMO Service Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global Peptide-Drug Conjugates(PDCs) CDMO Service Company Evaluation Quadrant

Table 14. Head Office of Key Peptide-Drug Conjugates(PDCs) CDMO Service Players

Table 15. Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Type Footprint

Table 16. Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Application Footprint

Table 17. Peptide-Drug Conjugates(PDCs) CDMO Service Mergers & Acquisitions Activity

Table 18. United States VS China Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China Peptide-Drug Conjugates(PDCs) CDMO Service

Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (States, Country)

Table 21. United States Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share (2021-2026)

Table 23. China Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (Province, Country)

Table 24. China Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share (2021-2026)

Table 26. Rest of World Based Peptide-Drug Conjugates(PDCs) CDMO Service Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share (2021-2026)

Table 29. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2027-2032) & (USD Million)

Table 32. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Capacity Tier, (USD Million), 2021 & 2025 & 2032

Table 33. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Value by Capacity Tier (2021-2026) & (USD Million)

Table 34. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Capacity Tier (2027-2032) & (USD Million)

Table 35. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Therapeutic Area, (USD Million), 2021 & 2025 & 2032

Table 36. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Value by Therapeutic Area (2021-2026) & (USD Million)

Table 37. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Therapeutic Area (2027-2032) & (USD Million)

Table 38. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 39. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026) & (USD Million)

Table 40. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2027-2032) & (USD Million)

Table 41. WuXi TIDES Basic Information, Manufacturing Base and Competitors

Table 42. WuXi TIDES Major Business

Table 43. WuXi TIDES Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 44. WuXi TIDES Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 45. WuXi TIDES Recent Developments/Updates

Table 46. WuXi TIDES Competitive Strengths & Weaknesses

Table 47. Porton Basic Information, Manufacturing Base and Competitors

Table 48. Porton Major Business

Table 49. Porton Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 50. Porton Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 51. Porton Recent Developments/Updates

Table 52. Porton Competitive Strengths & Weaknesses

Table 53. PeptiStar Basic Information, Manufacturing Base and Competitors

Table 54. PeptiStar Major Business

Table 55. PeptiStar Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 56. PeptiStar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 57. PeptiStar Recent Developments/Updates

Table 58. PeptiStar Competitive Strengths & Weaknesses

Table 59. Jiuzhou Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 60. Jiuzhou Pharmaceutical Major Business

Table 61. Jiuzhou Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 62. Jiuzhou Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 63. Jiuzhou Pharmaceutical Recent Developments/Updates

Table 64. Jiuzhou Pharmaceutical Competitive Strengths & Weaknesses

Table 65. CPC Scientific Basic Information, Manufacturing Base and Competitors

Table 66. CPC Scientific Major Business

Table 67. CPC Scientific Peptide-Drug Conjugates(PDCs) CDMO Service Product and

Services

Table 68. CPC Scientific Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 69. CPC Scientific Recent Developments/Updates

Table 70. CPC Scientific Competitive Strengths & Weaknesses

Table 71. Creative Peptides Basic Information, Manufacturing Base and Competitors

Table 72. Creative Peptides Major Business

Table 73. Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 74. Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 75. Creative Peptides Recent Developments/Updates

Table 76. Creative Peptides Competitive Strengths & Weaknesses

Table 77. Viva Biotech Basic Information, Manufacturing Base and Competitors

Table 78. Viva Biotech Major Business

Table 79. Viva Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 80. Viva Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 81. Viva Biotech Recent Developments/Updates

Table 82. Viva Biotech Competitive Strengths & Weaknesses

Table 83. KriSan Biotech Basic Information, Manufacturing Base and Competitors

Table 84. KriSan Biotech Major Business

Table 85. KriSan Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 86. KriSan Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 87. KriSan Biotech Recent Developments/Updates

Table 88. KriSan Biotech Competitive Strengths & Weaknesses

Table 89. ChemExpress Basic Information, Manufacturing Base and Competitors

Table 90. ChemExpress Major Business

Table 91. ChemExpress Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 92. ChemExpress Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 93. ChemExpress Recent Developments/Updates

Table 94. ChemExpress Competitive Strengths & Weaknesses

Table 95. CordenPharma Basic Information, Manufacturing Base and Competitors

Table 96. CordenPharma Major Business

Table 97. CordenPharma Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 98. CordenPharma Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 99. CordenPharma Recent Developments/Updates

Table 100. CordenPharma Competitive Strengths & Weaknesses

Table 101. Almac Group Basic Information, Manufacturing Base and Competitors

Table 102. Almac Group Major Business

Table 103. Almac Group Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 104. Almac Group Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 105. Almac Group Recent Developments/Updates

Table 106. Almac Group Competitive Strengths & Weaknesses

Table 107. AmbioPharm Basic Information, Manufacturing Base and Competitors

Table 108. AmbioPharm Major Business

Table 109. AmbioPharm Peptide-Drug Conjugates(PDCs) CDMO Service Product and Services

Table 110. AmbioPharm Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 111. AmbioPharm Recent Developments/Updates

Table 112. AmbioPharm Competitive Strengths & Weaknesses

Table 113. Global Key Players of Peptide-Drug Conjugates(PDCs) CDMO Service Upstream (Raw Materials)

Table 114. Global Peptide-Drug Conjugates(PDCs) CDMO Service Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Peptide-Drug Conjugates(PDCs) CDMO Service Picture
- Figure 2. World Peptide-Drug Conjugates(PDCs) CDMO Service Total Revenue: 2021 & 2025 & 2032, (USD Million)
- Figure 3. World Peptide-Drug Conjugates(PDCs) CDMO Service Total Revenue (2021-2032) & (USD Million)
- Figure 4. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
- Figure 5. World Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Region (2021-2032), (by Headquarter Location)
- Figure 6. United States Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032) & (USD Million)
- Figure 7. China Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032) & (USD Million)
- Figure 8. Europe Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032) & (USD Million)
- Figure 9. Japan Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032) & (USD Million)
- Figure 10. South Korea Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032) & (USD Million)
- Figure 11. ASEAN Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032) & (USD Million)
- Figure 12. India Based Company Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2021-2032) & (USD Million)
- Figure 13. Peptide-Drug Conjugates(PDCs) CDMO Service Market Drivers
- Figure 14. Factors Affecting Demand
- Figure 15. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032) & (USD Million)
- Figure 16. World Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Region (2021-2032)
- Figure 17. United States Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032) & (USD Million)
- Figure 18. China Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032) & (USD Million)
- Figure 19. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 23. India Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of Peptide-Drug Conjugates(PDCs) CDMO Service by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide-Drug Conjugates(PDCs) CDMO Service Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide-Drug Conjugates(PDCs) CDMO Service Markets in 2025

Figure 27. United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type in 2025

Figure 31. GMP Services

Figure 32. Non-GMP Services

Figure 33. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2021-2032)

Figure 34. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Capacity Tier, (USD Million), 2021 & 2025 & 2032

Figure 35. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Capacity Tier in 2025

Figure 36. Small-Scale Production

Figure 37. Pilot-Scale Production

Figure 38. Commercial-Scale Production

Figure 39. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Capacity Tier (2021-2032)

Figure 40. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Therapeutic Area, (USD Million), 2021 & 2025 & 2032

Figure 41. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Therapeutic Area in 2025

Figure 42. Oncology

Figure 43. Metabolic Diseases

Figure 44. Cardiovascular Diseases

Figure 45. Infectious Diseases

Figure 46. Neurological Disorder

Figure 47. Other

Figure 48. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Therapeutic Area (2021-2032)

Figure 49. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 50. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application in 2025

Figure 51. Pharmaceutical Companies

Figure 52. Biotechnology Companies

Figure 53. Academic and Research Institutions

Figure 54. Others

Figure 55. World Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2021-2032)

Figure 56. Peptide-Drug Conjugates(PDCs) CDMO Service Industrial Chain

Figure 57. Methodology

Figure 58. Research Process and Data Source

I would like to order

Product name: Global Peptide-Drug Conjugates(PDCs) CDMO Service Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G9F692F6E2CFEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9F692F6E2CFEN.html>